Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Fair Care Act of 2019
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. Drug Pricing. S.2543: Prescription Drug Pricing Reduction Act (PDPRA) of 2019. H.R.3: Lower Drug Costs Now Act of 2019.
Fair Care Act of 2019
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2019 · third_quarter · Q3
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. Drug Pricing. S.2543: Prescription Drug Pricing Reduction Act (PDPRA) of 2019. H.R.3: Lower Drug Costs Now Act of 2019.
Filing targets: Bureau of Citizenship & Immigration Services (BCIS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Source: Senate LDA
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. H.R.2296: FAIR Drug Pricing Act of 2019. H.R.987: Strengthening Health Care and Lowering Prescription Drug Costs Act. S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019. Rebate Rule Comments. FDA Natural History Studies for Drug Development. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. Prescription Drug User Fee Act (PDUFA) Reauthorization.
Fair Care Act of 2019
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. FDA-2018-N-4171: Patient Engagement in Medical Device Clinical Trials. Docket No. FDA-2018-D-4455-0001: Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data; Draft Guidance for Industry and Other Stakeholders. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. FR Document: 2019-01026 Citation: 84 FR 2340: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.
More Efficient Tools to Realize Information for Consumers Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. H.R.2296: FAIR Drug Pricing Act of 2019. H.R.987: Strengthening Health Care and Lowering Prescription Drug Costs Act. S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019. Rebate Rule Comments. FDA Natural History Studies for Drug Development. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. Prescription Drug User Fee Act (PDUFA) Reauthorization.
Elijah E. Cummings Lower Drug Costs Now Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. Drug Pricing. S.2543: Prescription Drug Pricing Reduction Act (PDPRA) of 2019. H.R.3: Lower Drug Costs Now Act of 2019.
CREATES Act of 2019
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. H.R.2296: FAIR Drug Pricing Act of 2019. H.R.987: Strengthening Health Care and Lowering Prescription Drug Costs Act. S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019. Rebate Rule Comments. FDA Natural History Studies for Drug Development. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. Prescription Drug User Fee Act (PDUFA) Reauthorization.
CREATES Act of 2019
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. FDA-2018-N-4171: Patient Engagement in Medical Device Clinical Trials. Docket No. FDA-2018-D-4455-0001: Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data; Draft Guidance for Industry and Other Stakeholders. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. FR Document: 2019-01026 Citation: 84 FR 2340: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.
Strengthening Health Care and Lowering Prescription Drug Costs Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. H.R.2296: FAIR Drug Pricing Act of 2019. H.R.987: Strengthening Health Care and Lowering Prescription Drug Costs Act. S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019. Rebate Rule Comments. FDA Natural History Studies for Drug Development. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. Prescription Drug User Fee Act (PDUFA) Reauthorization.
Prescription Drug Pricing Reduction Act of 2019
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. Drug Pricing. S.2543: Prescription Drug Pricing Reduction Act (PDPRA) of 2019. H.R.3: Lower Drug Costs Now Act of 2019.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. FDA-2018-N-4171: Patient Engagement in Medical Device Clinical Trials. Docket No. FDA-2018-D-4455-0001: Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data; Draft Guidance for Industry and Other Stakeholders. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. FR Document: 2019-01026 Citation: 84 FR 2340: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. H.R.2296: FAIR Drug Pricing Act of 2019. H.R.987: Strengthening Health Care and Lowering Prescription Drug Costs Act. S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019. Rebate Rule Comments. FDA Natural History Studies for Drug Development. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. Prescription Drug User Fee Act (PDUFA) Reauthorization.
Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. H.R.2296: FAIR Drug Pricing Act of 2019. H.R.987: Strengthening Health Care and Lowering Prescription Drug Costs Act. S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019. Rebate Rule Comments. FDA Natural History Studies for Drug Development. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. Prescription Drug User Fee Act (PDUFA) Reauthorization.
OPEN Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. Accelerated Approval. S.3000: Patient Advocacy Transparency Act. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
OPEN Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. H.R.5062: Advancing Access to Precision Medicine Act.
OPEN Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. Patient-focused drug development. Biological products marketplace. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Restoring the Patient's Voice Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Bipartisan Health Care Stabilization Act. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. S.428: Advancing Care for Exceptional Kids Act of 2017 or the ACE Kids Act of 2017. Congressionally Directed Medical Research Program. S.Res.423: A resolution designating February 28, 2018, as "Rare Disease Day". Short-term, limited-duration health plans. Association health plans. H.R.2077: Restoring the Patient's Voice Act of 2017.
Restoring the Patient's Voice Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. Senator Cassidy's "Ideas to Make Health Care Affordable Again" white paper. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Copay accumulator programs. Slowly progressive low-prevalence rare diseases. S.3388: Ensuring Coverage for Patients with Pre-Existing Conditions Act. Pediatric subspecialty loan repayment reauthorization. Medical expense deduction. Humanitarian Device Exemption (HDE) program. Risk adjustment payments.
Restoring the Patient's Voice Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Pediatric subspecialty loan repayment reauthorization. Human gene therapy for rare diseases. Newborn Screening Saves Lives Act reauthorization. Neurological Conditions Surveillance System funding. H.R.7102: ENROLL Act of 2018.
Medical Nutrition Equity Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Bipartisan Health Care Stabilization Act. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. S.428: Advancing Care for Exceptional Kids Act of 2017 or the ACE Kids Act of 2017. Congressionally Directed Medical Research Program. S.Res.423: A resolution designating February 28, 2018, as "Rare Disease Day". Short-term, limited-duration health plans. Association health plans. H.R.2077: Restoring the Patient's Voice Act of 2017.
Medical Nutrition Equity Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Congressionally Directed Medical Research Program. Short-term, limited-duration health plans. Association health plans.
Medical Nutrition Equity Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Pediatric subspecialty loan repayment reauthorization. Human gene therapy for rare diseases. Newborn Screening Saves Lives Act reauthorization. Neurological Conditions Surveillance System funding. H.R.7102: ENROLL Act of 2018.
Medical Nutrition Equity Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. Senator Cassidy's "Ideas to Make Health Care Affordable Again" white paper. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Copay accumulator programs. Slowly progressive low-prevalence rare diseases. S.3388: Ensuring Coverage for Patients with Pre-Existing Conditions Act. Pediatric subspecialty loan repayment reauthorization. Medical expense deduction. Humanitarian Device Exemption (HDE) program. Risk adjustment payments.
Advancing Access to Precision Medicine Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. H.R.5062: Advancing Access to Precision Medicine Act.
RARE Act of 2018
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Pediatric subspecialty loan repayment reauthorization. Human gene therapy for rare diseases. Newborn Screening Saves Lives Act reauthorization. Neurological Conditions Surveillance System funding. H.R.7102: ENROLL Act of 2018.
RARE Act of 2018
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Bipartisan Health Care Stabilization Act. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. S.428: Advancing Care for Exceptional Kids Act of 2017 or the ACE Kids Act of 2017. Congressionally Directed Medical Research Program. S.Res.423: A resolution designating February 28, 2018, as "Rare Disease Day". Short-term, limited-duration health plans. Association health plans. H.R.2077: Restoring the Patient's Voice Act of 2017.
RARE Act of 2018
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. Senator Cassidy's "Ideas to Make Health Care Affordable Again" white paper. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Copay accumulator programs. Slowly progressive low-prevalence rare diseases. S.3388: Ensuring Coverage for Patients with Pre-Existing Conditions Act. Pediatric subspecialty loan repayment reauthorization. Medical expense deduction. Humanitarian Device Exemption (HDE) program. Risk adjustment payments.
RARE Act of 2018
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Congressionally Directed Medical Research Program. Short-term, limited-duration health plans. Association health plans.
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Bipartisan Health Care Stabilization Act. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. S.428: Advancing Care for Exceptional Kids Act of 2017 or the ACE Kids Act of 2017. Congressionally Directed Medical Research Program. S.Res.423: A resolution designating February 28, 2018, as "Rare Disease Day". Short-term, limited-duration health plans. Association health plans. H.R.2077: Restoring the Patient's Voice Act of 2017.
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Congressionally Directed Medical Research Program. Short-term, limited-duration health plans. Association health plans.
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Appropriations for patients with rare diseases. National Institutes of Health Funding. Food and Drug Administration Funding. H.R.6157: Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019.
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Appropriations for patients with rare diseases. National Institutes of Health Funding. Food and Drug Administration Funding. H.R.6157: Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019.
ENROLL Act of 2018
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Pediatric subspecialty loan repayment reauthorization. Human gene therapy for rare diseases. Newborn Screening Saves Lives Act reauthorization. Neurological Conditions Surveillance System funding. H.R.7102: ENROLL Act of 2018.
Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases.
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. H.Res.1154/S.Res.690: Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases. Patient-focused drug development. Rare disease early development and the role of pre-investigational new drug application meetings. S.3519: MODERN Labeling Act.
Medical Nutrition Equity Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Congressionally Directed Medical Research Program. Short-term, limited-duration health plans. Association health plans.
Medical Nutrition Equity Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Pediatric subspecialty loan repayment reauthorization. Human gene therapy for rare diseases. Newborn Screening Saves Lives Act reauthorization. Neurological Conditions Surveillance System funding. H.R.7102: ENROLL Act of 2018.
Medical Nutrition Equity Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Bipartisan Health Care Stabilization Act. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. S.428: Advancing Care for Exceptional Kids Act of 2017 or the ACE Kids Act of 2017. Congressionally Directed Medical Research Program. S.Res.423: A resolution designating February 28, 2018, as "Rare Disease Day". Short-term, limited-duration health plans. Association health plans. H.R.2077: Restoring the Patient's Voice Act of 2017.
Medical Nutrition Equity Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. Senator Cassidy's "Ideas to Make Health Care Affordable Again" white paper. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Copay accumulator programs. Slowly progressive low-prevalence rare diseases. S.3388: Ensuring Coverage for Patients with Pre-Existing Conditions Act. Pediatric subspecialty loan repayment reauthorization. Medical expense deduction. Humanitarian Device Exemption (HDE) program. Risk adjustment payments.
Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. Patient-focused drug development. Biological products marketplace. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. H.R.5062: Advancing Access to Precision Medicine Act.
Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. Accelerated Approval. S.3000: Patient Advocacy Transparency Act. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Bipartisan Health Care Stabilization Act. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. S.428: Advancing Care for Exceptional Kids Act of 2017 or the ACE Kids Act of 2017. Congressionally Directed Medical Research Program. S.Res.423: A resolution designating February 28, 2018, as "Rare Disease Day". Short-term, limited-duration health plans. Association health plans. H.R.2077: Restoring the Patient's Voice Act of 2017.
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Congressionally Directed Medical Research Program. Short-term, limited-duration health plans. Association health plans.
Patient Advocacy Transparency Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Medicare issues impacting patients with rare diseases. Medicare Part D. Medicaid waivers. S.3000: Patient Advocacy Transparency Act. Inpatient Prospective Payment System (IPPS) proposed rule.
Patient Advocacy Transparency Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. Accelerated Approval. S.3000: Patient Advocacy Transparency Act. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Ensuring Coverage for Patients with Pre-Existing Conditions Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. Senator Cassidy's "Ideas to Make Health Care Affordable Again" white paper. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Copay accumulator programs. Slowly progressive low-prevalence rare diseases. S.3388: Ensuring Coverage for Patients with Pre-Existing Conditions Act. Pediatric subspecialty loan repayment reauthorization. Medical expense deduction. Humanitarian Device Exemption (HDE) program. Risk adjustment payments.
MODERN Labeling Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. H.Res.1154/S.Res.690: Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases. Patient-focused drug development. Rare disease early development and the role of pre-investigational new drug application meetings. S.3519: MODERN Labeling Act.
ACE Kids Act of 2017
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Bipartisan Health Care Stabilization Act. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. S.428: Advancing Care for Exceptional Kids Act of 2017 or the ACE Kids Act of 2017. Congressionally Directed Medical Research Program. S.Res.423: A resolution designating February 28, 2018, as "Rare Disease Day". Short-term, limited-duration health plans. Association health plans. H.R.2077: Restoring the Patient's Voice Act of 2017.
A resolution designating February 28, 2018, as "Rare Disease Day".
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Bipartisan Health Care Stabilization Act. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. S.428: Advancing Care for Exceptional Kids Act of 2017 or the ACE Kids Act of 2017. Congressionally Directed Medical Research Program. S.Res.423: A resolution designating February 28, 2018, as "Rare Disease Day". Short-term, limited-duration health plans. Association health plans. H.R.2077: Restoring the Patient's Voice Act of 2017.
A resolution affirming the importance of the Orphan Drug Act, applauding the life-saving accomplishments of the Act during its 35-year history, and recognizing the need to continue support for research and development of new therapies for rare diseases.
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. H.Res.1154/S.Res.690: Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases. Patient-focused drug development. Rare disease early development and the role of pre-investigational new drug application meetings. S.3519: MODERN Labeling Act.
2019 · second_quarter · Q2
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. H.R.2296: FAIR Drug Pricing Act of 2019. H.R.987: Strengthening Health Care and Lowering Prescription Drug Costs Act. S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019. Rebate Rule Comments. FDA Natural History Studies for Drug Development. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. Prescription Drug User Fee Act (PDUFA) Reauthorization.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2019 · first_quarter · Q1
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Orphan Drug Tax Credit. H.R.1332: Fair Care Act of 2019. FDA-2018-N-4171: Patient Engagement in Medical Device Clinical Trials. Docket No. FDA-2018-D-4455-0001: Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data; Draft Guidance for Industry and Other Stakeholders. Docket No. FDA-2015-D-2818: Rare Diseases: Common Issues in Drug Development, Guidance For Industry; Draft Guidance. H.R.965/S.340: CREATES Act of 2019. FR Document: 2019-01026 Citation: 84 FR 2340: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2018 · fourth_quarter · 4A
Medicare issues impacting patients with rare diseases. Medicare Part D. Step therapy in Medicare Advantage plans. Section 1115 waivers. Section 1332 waivers. Copay accumulator programs. Medicaid expansion. International pricing index model for Medicare part B drugs.
Appropriations for patients with rare diseases. National Institutes of Health Funding. Food and Drug Administration Funding. H.R.6157: Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019.
Pharmaceutical issues impacting patients with rare diseases. H.Res.1154/S.Res.690: Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases. Patient-focused drug development. Rare disease early development and the role of pre-investigational new drug application meetings. S.3519: MODERN Labeling Act.
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Pediatric subspecialty loan repayment reauthorization. Human gene therapy for rare diseases. Newborn Screening Saves Lives Act reauthorization. Neurological Conditions Surveillance System funding. H.R.7102: ENROLL Act of 2018.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2018 · third_quarter · 3A
Pharmaceutical issues impacting patients with rare diseases. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. Patient-focused drug development. Biological products marketplace. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Appropriations for patients with rare diseases. National Institutes of Health Funding. Food and Drug Administration Funding. H.R.6157: Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019.
Medicare issues impacting patients with rare diseases. Medicare Part D. Step therapy in Medicare Advantage plans. Medicaid waivers. Section 1332 waivers. Medicaid expansion.
Health issues impacting patients with rare diseases. H.R.2077: Restoring the Patient's Voice Act of 2017. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. Senator Cassidy's "Ideas to Make Health Care Affordable Again" white paper. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Short-term, limited-duration health plans. Association health plans. Copay accumulator programs. Slowly progressive low-prevalence rare diseases. S.3388: Ensuring Coverage for Patients with Pre-Existing Conditions Act. Pediatric subspecialty loan repayment reauthorization. Medical expense deduction. Humanitarian Device Exemption (HDE) program. Risk adjustment payments.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2018 · second_quarter · 2A
Health issues impacting patients with rare diseases. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. Congressionally Directed Medical Research Program. Short-term, limited-duration health plans. Association health plans.
Appropriations for patients with rare diseases. National Institutes of Health Funding. Food and Drug Administration Funding.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2018 · first_quarter · 1A
Medicare issues impacting patients with rare diseases. Medicare Part D.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. H.R.5062: Advancing Access to Precision Medicine Act.
Health issues impacting patients with rare diseases. Bipartisan Health Care Stabilization Act. H.R.5247/S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018. H.R.5115: Rare Disease Advancement, Research, and Education (RARE) Act of 2018. H.R.2587/S.1194: S.1194 - Medical Nutrition Equity Act of 2017. S.428: Advancing Care for Exceptional Kids Act of 2017 or the ACE Kids Act of 2017. Congressionally Directed Medical Research Program. S.Res.423: A resolution designating February 28, 2018, as "Rare Disease Day". Short-term, limited-duration health plans. Association health plans. H.R.2077: Restoring the Patient's Voice Act of 2017.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2009 · second_quarter · Q2
Follow-on Biologics Food & Drug Administration Compassionate Allowances (Social Security Administration)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2009 · first_quarter · Q1
Follow-on Biologics Healthcare Reform Food & Drug Adminsitration Food & Drug Administration Appropriations Compassionate Allowances (Social Security Administration)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2008 · fourth_quarter · Q4
Follow-on Biologics Healthcare Reform Food & Drug Administrtation Newborn Screening Food & Drug Administration Appropriations Compassionate Allowances (Scoial Security Adminsitration)
Filing targets: HOUSE OF REPRESENTATIVES
Medicare issues impacting patients with rare diseases. Medicare Part D. Medicaid waivers. S.3000: Patient Advocacy Transparency Act. Inpatient Prospective Payment System (IPPS) proposed rule.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017. Accelerated Approval. S.3000: Patient Advocacy Transparency Act. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Appropriations for patients with rare diseases. National Institutes of Health Funding. Food and Drug Administration Funding. Pediatric Device Consortia Grant Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE